<?xml version="1.0" ?>
<document id="04034022f265da392051b3e3fcef2e580247d6c4">
  <chunk id="04034022f265da392051b3e3fcef2e580247d6c4.c0" text="Marburg virus-like particles by co- expression of glycoprotein and matrix protein in insect cells induces immune responses in mice">
    <entity charOffset="50-62" id="04034022f265da392051b3e3fcef2e580247d6c4.c0.e0" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="74-81" id="04034022f265da392051b3e3fcef2e580247d6c4.c0.e1" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
  </chunk>
  <chunk id="04034022f265da392051b3e3fcef2e580247d6c4.c1" text="Background: Marburg virus (MARV) causes severe haemorrhagic fever in humans and nonhuman primates and has a high mortality rate. However, effective drugs or licensed vaccines are not currently available to control the outbreak and spread of this disease.">
    <entity charOffset="148-153" id="04034022f265da392051b3e3fcef2e580247d6c4.c1.e0" ontology_id="CHEBI_23888" text="drugs" type="chemical"/>
  </chunk>
  <chunk id="04034022f265da392051b3e3fcef2e580247d6c4.c2" text="Methods: In this study, we generated MARV virus-like particles (VLPs) by co-expressing the glycoprotein (GP) and matrix protein (VP40) using the baculovirus expression system. MARV VLPs and three adjuvants, Poria cocos polysaccharide (PCP-II), poly(I:C) and aluminium hydroxide, were evaluated after intramuscular vaccination in mice.">
    <entity charOffset="91-103" id="04034022f265da392051b3e3fcef2e580247d6c4.c2.e0" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="120-127" id="04034022f265da392051b3e3fcef2e580247d6c4.c2.e1" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="219-233" id="04034022f265da392051b3e3fcef2e580247d6c4.c2.e2" ontology_id="CHEBI_18154" text="polysaccharide" type="chemical"/>
    <entity charOffset="258-267" id="04034022f265da392051b3e3fcef2e580247d6c4.c2.e3" ontology_id="CHEBI_28984" text="aluminium" type="chemical"/>
  </chunk>
  <chunk id="04034022f265da392051b3e3fcef2e580247d6c4.c3" text="Results: Murine studies demonstrated that vaccination with the MARV VLPs induce neutralizing antibodies and cellar immune responses. MARV VLPs and the PCP-II adjuvant group resulted in high titres of MARV-specific antibodies, activated relatively higher numbers of B cells and T cells in peripheral blood mononuclear cells (PBMCs), and induced greater cytokine secretion from splenocytes than the other adjuvants. Conclusion: MARV VLPs with the PCP-II adjuvant may constitute an effective vaccination and PCP-II should be further investigated as a novel adjuvant.">
    <entity charOffset="158-166" id="04034022f265da392051b3e3fcef2e580247d6c4.c3.e0" ontology_id="CHEBI_60809" text="adjuvant" type="chemical"/>
    <entity charOffset="403-412" id="04034022f265da392051b3e3fcef2e580247d6c4.c3.e1" ontology_id="CHEBI_60809" text="adjuvants" type="chemical"/>
    <entity charOffset="452-460" id="04034022f265da392051b3e3fcef2e580247d6c4.c3.e2" ontology_id="CHEBI_60809" text="adjuvant" type="chemical"/>
    <entity charOffset="554-562" id="04034022f265da392051b3e3fcef2e580247d6c4.c3.e3" ontology_id="CHEBI_60809" text="adjuvant" type="chemical"/>
  </chunk>
</document>
